NCT07121829 - Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 2, 2022

Primary Completion Date

December 18, 2024

Study Completion Date

December 18, 2024

Conditions

MelanomaSolid TumorPilocytic AstrocytomaNon Small Cell Lung CancerColorectal CancerPancreatic CancerMAP Kinase Family Gene MutationRAS MutationRAF MutationMEK Mutation

Interventions

DRUG

Tovorafenib

Tovorafenib tablet for oral use.

DRUG

Tovorafenib Drug: Pimasertib

Tovorafenib tablet for oral use. Pimasertib capsule for oral use

Trial Locations (10)

15213

UPMC Hillman Cancer Center, Pittsburgh

32256

Cancer Specialists of North Florida, Jacksonville

37232

vanderbilt-Ingram Cancer Center, Nashville

46250

Community North Cancer Center, Indianapolis

80045

University of Colorado Hospital, Aurora

90025

The Angeles Clinic, Los Angeles

92663

Hoag Health, Newport Beach

97239

OHSU Knight Cancer Institute, Portland

Unknown

Princess Margaret Cancer Centre, Toronto

The Hospital for Sick Children, Toronto